Compare VERA & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | HTGC |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.1B |
| IPO Year | 2021 | N/A |
| Metric | VERA | HTGC |
|---|---|---|
| Price | $33.93 | $15.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $81.30 | $18.86 |
| AVG Volume (30 Days) | 969.5K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | $472.48 | $5.24 |
| P/E Ratio | ★ N/A | $8.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.76 | $13.70 |
| 52 Week High | $56.05 | $19.67 |
| Indicator | VERA | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 39.09 | 43.99 |
| Support Level | $34.04 | $15.24 |
| Resistance Level | $42.77 | $16.08 |
| Average True Range (ATR) | 1.94 | 0.36 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 17.80 | 9.46 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.